Published in Hepatology on December 01, 2007
Toll-like receptors and cancer. Nat Rev Cancer (2008) 4.29
Lymph node fibroblastic reticular cells directly present peripheral tissue antigen under steady-state and inflammatory conditions. J Exp Med (2010) 2.37
Toll-like receptors as targets in chronic liver diseases. Gut (2009) 2.29
Living in the liver: hepatic infections. Nat Rev Immunol (2012) 2.03
Hepatitis B virus polymerase blocks pattern recognition receptor signaling via interaction with DDX3: implications for immune evasion. PLoS Pathog (2010) 1.33
Hepatitis B virus lacks immune activating capacity, but actively inhibits plasmacytoid dendritic cell function. PLoS One (2011) 1.27
Toll-like receptor-induced innate immune responses in non-parenchymal liver cells are cell type-specific. Immunology (2009) 1.21
The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases. Hepatol Int (2010) 1.12
Hepatitis B virus regulatory HBx protein binds to adaptor protein IPS-1 and inhibits the activation of beta interferon. J Virol (2010) 1.12
Innate immune responses in hepatitis B virus (HBV) infection. Virol J (2014) 1.11
Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis. Fibrogenesis Tissue Repair (2010) 1.09
Macrophages in hepatitis B and hepatitis C virus infections. J Virol (2008) 1.05
Toll-like receptors in liver fibrosis: cellular crosstalk and mechanisms. Front Physiol (2012) 1.05
Subversion of innate defenses by the interplay between DENV and pre-existing enhancing antibodies: TLRs signaling collapse. PLoS Negl Trop Dis (2010) 1.04
Inhibition of dengue and chikungunya virus infections by RIG-I-mediated type I interferon-independent stimulation of the innate antiviral response. J Virol (2014) 1.03
Inhibition of pattern recognition receptor-mediated inflammation by bioactive phytochemicals. Nutr Rev (2011) 1.00
Liver immunology. Compr Physiol (2013) 0.99
Small interfering RNAs induce target-independent inhibition of tumor growth and vasculature remodeling in a mouse model of hepatocellular carcinoma. Am J Pathol (2010) 0.98
Contribution of Toll-like receptors to the control of hepatitis B virus infection by initiating antiviral innate responses and promoting specific adaptive immune responses. Cell Mol Immunol (2014) 0.97
Activation of Toll-like receptor 3 impairs the dengue virus serotype 2 replication through induction of IFN-β in cultured hepatoma cells. PLoS One (2011) 0.95
Hepatitis B virus X protein suppresses virus-triggered IRF3 activation and IFN-beta induction by disrupting the VISA-associated complex. Cell Mol Immunol (2010) 0.94
Toll-like receptors in the pathogenesis of alcoholic liver disease. Gastroenterol Res Pract (2010) 0.93
Role of innate immune response in non-alcoholic Fatty liver disease: metabolic complications and therapeutic tools. Front Immunol (2014) 0.92
Association of Toll-like receptor 3 polymorphisms with chronic hepatitis B and hepatitis B-related acute-on-chronic liver failure. Inflammation (2013) 0.90
Therapeutic strategies for a functional cure of chronic hepatitis B virus infection. Acta Pharm Sin B (2014) 0.89
Selective hyper-responsiveness of the interferon system in major depressive disorders and depression induced by interferon therapy. PLoS One (2012) 0.88
Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection. Med Microbiol Immunol (2014) 0.88
Poly(I:C) treatment leads to interferon-dependent clearance of hepatitis B virus in a hydrodynamic injection mouse model. J Virol (2014) 0.86
Immunological functions of liver sinusoidal endothelial cells. Cell Mol Immunol (2016) 0.86
The role of innate immunity in HBV infection. Semin Immunopathol (2012) 0.85
Cancer-derived immunoglobulin G promotes LPS-induced proinflammatory cytokine production via binding to TLR4 in cervical cancer cells. Oncotarget (2014) 0.85
Susceptibility of different hepatitis B virus isolates to interferon-alpha in a mouse model based on hydrodynamic injection. PLoS One (2014) 0.84
Toll-like receptor 3 in liver diseases. Gastroenterol Res Pract (2010) 0.84
Tickling the TLR7 to cure viral hepatitis. J Transl Med (2014) 0.83
Crosstalk between innate and adaptive immunity in hepatitis B virus infection. World J Hepatol (2015) 0.83
STING agonists induce an innate antiviral immune response against hepatitis B virus. Antimicrob Agents Chemother (2014) 0.82
Toll-like receptors signaling contributes to immunopathogenesis of HBV infection. Gastroenterol Res Pract (2011) 0.82
Therapeutic Antiviral Effect of the Nucleic Acid Polymer REP 2055 against Persistent Duck Hepatitis B Virus Infection. PLoS One (2015) 0.82
The role of chemokines in hepatitis C virus-mediated liver disease. Int J Mol Sci (2014) 0.81
Downregulation of toll-like receptor 4 induces suppressive effects on hepatitis B virus-related hepatocellular carcinoma via ERK1/2 signaling. BMC Cancer (2015) 0.80
Treatment of chronic hepatitis B with pattern recognition receptor agonists: Current status and potential for a cure. Antiviral Res (2015) 0.80
Epigenetic modification of TLR4 promotes activation of NF-κB by regulating methyl-CpG-binding domain protein 2 and Sp1 in gastric cancer. Oncotarget (2016) 0.80
Development of a spontaneous liver disease resembling autoimmune hepatitis in mice lacking tyro3, axl and mer receptor tyrosine kinases. PLoS One (2013) 0.80
HIV Infection and TLR Signalling in the Liver. Gastroenterol Res Pract (2012) 0.79
Characterization of a Novel Human-Specific STING Agonist that Elicits Antiviral Activity Against Emerging Alphaviruses. PLoS Pathog (2015) 0.79
Intrahepatic Toll-Like Receptor 3 in Chronic HBV Infection Subjects: Asymptomatic Carriers, Active Chronic Hepatitis, Cirrhosis, and Hepatocellular Carcinoma. Hepat Mon (2016) 0.79
Saturated Fatty Acid inhibits viral replication in chronic hepatitis B virus infection with nonalcoholic Fatty liver disease by toll-like receptor 4-mediated innate immune response. Hepat Mon (2015) 0.79
Design of therapeutic vaccines: hepatitis B as an example. Microb Biotechnol (2011) 0.79
Control of hepatitis B virus replication by interferons and Toll-like receptor signaling pathways. World J Gastroenterol (2014) 0.79
The potential interplay of adipokines with toll-like receptors in the development of hepatocellular carcinoma. Gastroenterol Res Pract (2011) 0.78
Hepatitis B virus genome replication triggers toll-like receptor 3-dependent interferon responses in the absence of hepatitis B surface antigen. Sci Rep (2016) 0.78
Mechanism of Hepatitis B Virus Persistence in Hepatocytes and Its Carcinogenic Potential. Clin Infect Dis (2016) 0.77
A336C/A336T/T337C variations in HBV core gene and spontaneous hepatitis B e antigen loss in chronic hepatitis B patients. Virol J (2011) 0.77
Hepatitis B virus induces expression of cholesterol metabolism-related genes via TLR2 in HepG2 cells. World J Gastroenterol (2013) 0.77
Tumour viruses and innate immunity. Philos Trans R Soc Lond B Biol Sci (2017) 0.76
Molecular Evolution and Phylodynamics of Acute Hepatitis B Virus in Japan. PLoS One (2016) 0.75
MITA/STING and Its Alternative Splicing Isoform MRP Restrict Hepatitis B Virus Replication. PLoS One (2017) 0.75
Anti-viral role of toll like receptor 4 in hepatitis B virus infection: An in vitro study. World J Gastroenterol (2016) 0.75
TLR3 Plays Significant Roles against HBV-Associated HCC. Gastroenterol Res Pract (2015) 0.75
Nucleic acid-based polymers effective against hepatitis B Virus infection in patients don't harbor immunostimulatory properties in primary isolated liver cells. Sci Rep (2017) 0.75
Current progress in the development of therapeutic vaccines for chronic hepatitis B virus infection. Iran J Basic Med Sci (2016) 0.75
Changes in innate and permissive immune responses after hbv transgenic mouse vaccination and long-term-siRNA treatment [corrected]. PLoS One (2013) 0.75
Toll-like receptors in pathophysiology of liver diseases. World J Hepatol (2016) 0.75
Innate immune recognition of hepatitis B virus. World J Hepatol (2015) 0.75
Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. Lancet Infect Dis (2013) 4.87
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol (2012) 3.88
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet (2005) 3.33
Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology (2002) 3.16
Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A (2007) 3.13
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol (2012) 3.04
Low-molecular-weight heparin in patients with advanced cirrhosis. Liver Int (2010) 2.96
Cytokeratin 18-based modification of the MELD score improves prediction of spontaneous survival after acute liver injury. J Hepatol (2010) 2.71
Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology (2010) 2.60
Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology (2012) 2.46
Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation. N Engl J Med (2014) 2.39
Toll-like receptor 2 enhances ZO-1-associated intestinal epithelial barrier integrity via protein kinase C. Gastroenterology (2004) 2.33
The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies. J Virol (2013) 2.10
Biliary complications after liver transplantation: addition of T1-weighted images to MR cholangiopancreatography facilitates detection of cast in biliary cast syndrome. Radiology (2012) 2.01
Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution. Hepatology (2006) 1.96
Mutational switch of an IL-6 response to an interferon-gamma-like response. Proc Natl Acad Sci U S A (2002) 1.96
Obesity affects the liver - the link between adipocytes and hepatocytes. Digestion (2010) 1.96
Aortoesophageal fistula after thoracic aortic stent-graft placement: a rare but catastrophic complication of a novel emerging technique. JACC Cardiovasc Interv (2009) 1.94
Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer (2011) 1.89
The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol (2011) 1.87
Aortoesophageal fistula secondary to stent-graft repair of the thoracic aorta. J Endovasc Ther (2004) 1.85
Commensal-associated molecular patterns induce selective toll-like receptor-trafficking from apical membrane to cytoplasmic compartments in polarized intestinal epithelium. Am J Pathol (2002) 1.80
Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 1: epidemiology, environmental predispositions, clinical manifestations, and therapy. Lancet Infect Dis (2002) 1.80
Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. Hepatology (2013) 1.78
The interferon stimulated gene 15 functions as a proviral factor for the hepatitis C virus and as a regulator of the IFN response. Gut (2010) 1.77
Immunogenicity of combined hepatitis A and B vaccine in elderly persons. Vaccine (2003) 1.72
Coexistence of hepatitis B surface antigen (HBsAg) and heterologous subtype-specific antibodies to HBsAg among patients with chronic hepatitis B virus infection. Clin Infect Dis (2007) 1.69
Living-related liver transplantation from the view of the donor: a 1-year follow-up survey. Transplantation (2002) 1.66
Role of Toll-like receptor 2 in the immune response against hepadnaviral infection. J Hepatol (2012) 1.62
Natural regulatory T cells and persistent viral infection. J Virol (2007) 1.62
Intrahepatic CD8+ T-cell failure during chronic hepatitis C virus infection. Hepatology (2005) 1.61
Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology (2009) 1.59
Awareness of rabies risks and knowledge about preventive measures among experienced German travel health advisors. J Travel Med (2006) 1.59
Endoscopic therapy of posttransplant biliary stenoses after right-sided adult living donor liver transplantation. Clin Gastroenterol Hepatol (2005) 1.58
BLT-humanized C57BL/6 Rag2-/-γc-/-CD47-/- mice are resistant to GVHD and develop B- and T-cell immunity to HIV infection. Blood (2013) 1.57
Kinetics of CD8+ effector T cell responses and induced CD4+ regulatory T cell responses during Friend retrovirus infection. Eur J Immunol (2006) 1.56
Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial. J Hepatol (2006) 1.54
Role of microRNA-199a-5p and discoidin domain receptor 1 in human hepatocellular carcinoma invasion. Mol Cancer (2010) 1.51
Risk of hepatitis C virus transmission from an infected gynecologist to patients: results of a 7-year retrospective investigation. Arch Intern Med (2002) 1.51
Predictors of graft and patient survival in hepatitis C virus (HCV) recipients: model to predict HCV cirrhosis after liver transplantation. Transplantation (2007) 1.51
Suppression of acute anti-friend virus CD8+ T-cell responses by coinfection with lactate dehydrogenase-elevating virus. J Virol (2007) 1.50
Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication. Hepatology (2012) 1.49
MR colonography vs. optical colonoscopy: comparison of patients' acceptance in a screening population. Eur Radiol (2007) 1.48
Magnetic endoscopic imaging saves abdominal compression and patient pain in routine colonoscopies. J Dig Dis (2011) 1.47
Colitis-associated variant of TLR2 causes impaired mucosal repair because of TFF3 deficiency. Gastroenterology (2009) 1.46
Validation of putative reference genes for gene expression studies in human hepatocellular carcinoma using real-time quantitative RT-PCR. BMC Cancer (2008) 1.44
Daily low-dose tacrolimus is a safe and effective immunosuppressive regimen during telaprevir-based triple therapy for hepatitis C virus recurrence after liver transplant. Transplantation (2015) 1.44
Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response. Hepatology (2012) 1.43
Dissecting the interferon-induced inhibition of hepatitis C virus replication by using a novel host cell line. J Virol (2005) 1.41
Antiviral treatment of chronic hepatitis B with lamivudine in pediatric renal transplantation. Pediatr Transplant (2006) 1.39
Serum versus intrahepatic HCV RNA and liver histology. Hepatology (2002) 1.39
Elevated gamma-glutamyltransferase is associated with mortality in lung transplantation for cystic fibrosis. Transpl Int (2011) 1.39
Intrahepatic B-cell follicles of chronically hepatitis C virus-infected individuals lack signs of an ectopic germinal center reaction. Eur J Immunol (2014) 1.39
Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. J Hepatol (2012) 1.34
Evolution of raltegravir resistance during therapy. J Antimicrob Chemother (2009) 1.33
Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma. Lancet Infect Dis (2002) 1.31
Right living donor liver transplantation: an option for adult patients: single institution experience with 74 patients. Ann Surg (2003) 1.31
Modulation of hepatitis B virus replication and hepatocyte differentiation by MicroRNA-1. Hepatology (2011) 1.30
Quantitative liver function tests in donors and recipients of living donor liver transplantation. Liver Transpl (2006) 1.30
Analysis of the evolutionary forces in an immunodominant CD8 epitope in hepatitis C virus at a population level. J Virol (2008) 1.28
Mouse SAMHD1 has antiretroviral activity and suppresses a spontaneous cell-intrinsic antiviral response. Cell Rep (2013) 1.28
Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets. Clin Cancer Res (2004) 1.27
Transient depletion of regulatory T cells in transgenic mice reactivates virus-specific CD8+ T cells and reduces chronic retroviral set points. Proc Natl Acad Sci U S A (2011) 1.26
CD8+ T-cell dysfunction due to cytolytic granule deficiency in persistent Friend retrovirus infection. J Virol (2005) 1.26
Regulatory T cells suppress antiviral immune responses and increase viral loads during acute infection with a lymphotropic retrovirus. PLoS Pathog (2009) 1.26
TLR2 mediates gap junctional intercellular communication through connexin-43 in intestinal epithelial barrier injury. J Biol Chem (2009) 1.25
Development and functional consequences of LPS tolerance in sinusoidal endothelial cells of the liver. J Leukoc Biol (2005) 1.24
Virological and immunological determinants of intrahepatic virus-specific CD8+ T-cell failure in chronic hepatitis C virus infection. Hepatology (2008) 1.24
VEGF is important for early liver regeneration after partial hepatectomy. J Surg Res (2007) 1.24
Virus-specific CD8+ T cells upregulate programmed death-1 expression during acute friend retrovirus infection but are highly cytotoxic and control virus replication. J Immunol (2011) 1.23
Immune control and prevention of chronic Friend retrovirus infection. Front Biosci (2007) 1.23
Volumetric and functional recovery of the liver after right hepatectomy for living donation. Liver Transpl (2004) 1.22
Acute liver failure is associated with elevated liver stiffness and hepatic stellate cell activation. Hepatology (2010) 1.22
Balloon dilatation vs. balloon dilatation plus bile duct endoprostheses for treatment of anastomotic biliary strictures after liver transplantation. Liver Transpl (2006) 1.22
Toll-like receptor-induced innate immune responses in non-parenchymal liver cells are cell type-specific. Immunology (2009) 1.21
Sequence diversity of hepatitis C virus: implications for immune control and therapy. World J Gastroenterol (2007) 1.21